Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. WuXi AppTec Co., Ltd.
  6. Summary
    603259   CNE1000031K4

WUXI APPTEC CO., LTD.

(603259)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
146.32 141.6 141.8 136.72 136.68 Last
21286230 21898970 14177810 19096190 13291200 Volume
+1.61% -3.23% +0.14% -3.58% -0.03% Change
Estimated financial data (e)
Sales 2021 22 502 M 3 547 M 3 547 M
Net income 2021 4 462 M 703 M 703 M
Net cash position 2021 7 385 M 1 164 M 1 164 M
P/E ratio 2021 90,0x
Yield 2021 0,31%
Sales 2022 29 776 M 4 693 M 4 693 M
Net income 2022 5 860 M 924 M 924 M
Net cash position 2022 9 794 M 1 544 M 1 544 M
P/E ratio 2022 67,5x
Yield 2022 0,40%
Capitalization 402 B 63 075 M 63 305 M
EV / Sales 2021 17,5x
EV / Sales 2022 13,2x
Nbr of Employees 33 305
Free-Float 58,8%
More Financials
Company
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (65,7%): small molecules discovery services, bioanalytical services, medical devices safety testing... 
More about the company
Ratings of WuXi AppTec Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about WUXI APPTEC CO., LTD.
11/15WUXI APPTEC : ATU Opens New Facility in Philadelphia, Tripling Testing Capacity to Support..
PU
11/08Hoth Therapeutics, Inc. Inks API and Drug Product Contracts with STA Pharmaceutical to ..
CI
11/01WuXi Apptec's Q3 Profit Jumps 36.2% on Higher Capacity Utilization; Hong Kong Shares Dr..
MT
10/29WuXi AppTec Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, ..
CI
10/29WuXi AppTec Reports Strong Third-Quarter 2021 Results
PU
10/29WuXi AppTec Third Quarter 2021 Earnings Presentation
PU
10/292021 third quarterly
PU
10/17WUXI APPTEC : ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services f..
PU
10/06SIRONA BIOCHEM : On Advancement of TFC-1067 Compound
MT
09/22DMD : Charting the Path for New Therapeutics and Better Care
PU
08/25WUXI APPTEC : Investor Day - Industry Trend and Company Strategy
PU
08/25WUXI APPTEC : Investor Day - Financial Performance
PU
08/25WUXI APPTEC : Investor Day - WuXi Biology
PU
08/25WUXI APPTEC : Investor Day - WuXi Chemistry
PU
08/25WUXI APPTEC : Investor Day - WuXi Testing
PU
More news
News in other languages on WUXI APPTEC CO., LTD.
11/01Le bénéfice de WuXi Apptec au troisième trimestre bondit de 36,2 % en raison d'une meil..
08/13Le bénéfice de WuXi Apptec au premier semestre augmente de 56 % grâce à des revenus éle..
07/16Wuxi Apptec s'attend à une croissance de 55 % de son bénéfice au premier semestre
07/15WuXi AppTec Co., Ltd. fournit des prévisions de résultats pour les six mois se terminan..
07/06UPDATE/MÄRKTE ASIEN/Richtungswechsel in Sydney nach RBA-Beschlüssen
More news
Analyst Recommendations on WUXI APPTEC CO., LTD.
More recommendations
Chart WUXI APPTEC CO., LTD.
Duration : Period :
WuXi AppTec Co., Ltd. Technical Analysis Chart | 603259 | CNE1000031K4 | MarketScreener
Technical analysis trends WUXI APPTEC CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 136,68 CNY
Average target price 183,50 CNY
Spread / Average Target 34,3%
EPS Revisions
Managers and Directors
Min Zhang Chen Co-Chief Executive Officer
Qing Yang Co-CEO, Executive Director & Executive VP
Ge Li Chairman & President
Ellis Chu Chief Financial Officer & Senior Vice President
Harry He Chairman-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
WUXI APPTEC CO., LTD.21.75%63 075
GILEAD SCIENCES, INC.19.55%87 368
BIONTECH SE243.27%73 106
REGENERON PHARMACEUTICALS31.46%66 402
VERTEX PHARMACEUTICALS-13.17%52 178
BEIGENE, LTD.22.78%32 604